967,825 Shares in iRadimed Corporation $IRMD Purchased by BlackRock Inc.

Key Points

• BlackRock acquired 967,825 shares of iRadimed, valued at approximately $92.5 million, giving it a 7.57% stake. Institutional investors collectively own 92.34% of the company.
• iRadimed exceeded quarterly expectations with EPS of $0.46 versus the $0.44 consensus and revenue of $20.47 million. The company provided fiscal 2026 EPS guidance of $2.09–$2.24 and pays a quarterly dividend of $0.20.
• Analyst sentiment remains a “Moderate Buy”, with a consensus price target of $120, although two research firms recently downgraded the stock to “Hold.” Shares opened at $87.07, below the 52-week high of $107.90.

BlackRock Inc. purchased a new stake in iRadimed Corporation (NASDAQ:IRMD - Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 967,825 shares of the medical equipment provider's stock, valued at approximately $92,485,000. BlackRock Inc. owned approximately 7.57% of iRadimed as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in IRMD. Quarry LP bought a new stake in shares of iRadimed during the 3rd quarter worth approximately $40,000. Farther Finance Advisors LLC increased its stake in shares of iRadimed by 827.1% during the 4th quarter. Farther Finance Advisors LLC now owns 445 shares of the medical equipment provider's stock worth $43,000 after purchasing an additional 397 shares during the last quarter. Tower Research Capital LLC TRC raised its stake in iRadimed by 191.1% in the second quarter. Tower Research Capital LLC TRC now owns 754 shares of the medical equipment provider's stock valued at $45,000 after buying an additional 495 shares during the period. CWM LLC raised its stake in iRadimed by 19.5% in the fourth quarter. CWM LLC now owns 657 shares of the medical equipment provider's stock valued at $64,000 after buying an additional 107 shares during the period. Finally, Global Retirement Partners LLC acquired a new stake in shares of iRadimed in the second quarter valued at approximately $84,000. Institutional investors and hedge funds own 92.34% of the company's stock.

Insiders Place Their Bets

In other news, CEO Roger E. Susi sold 2,500 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $90.60, for a total transaction of $226,500.00. Following the completion of the sale, the chief executive officer directly owned 2,162,500 shares in the company, valued at approximately $195,922,500. This represents a 0.12% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 34.60% of the stock is owned by corporate insiders.

iRadimed Stock Performance

IRMD opened at $87.07 on Friday. iRadimed Corporation has a fifty-two week low of $67.84 and a fifty-two week high of $107.90. The company has a market capitalization of $1.11 billion, a P/E ratio of 48.64 and a beta of 0.90. The stock has a fifty day moving average of $92.96 and a 200-day moving average of $94.18.

iRadimed (NASDAQ:IRMD - Get Free Report) last announced its earnings results on Friday, July 31st. The medical equipment provider reported $0.46 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.44 by $0.02. iRadimed had a net margin of 26.70% and a return on equity of 23.45%. The firm had revenue of $20.47 million for the quarter, compared to analyst estimates of $20.35 million. iRadimed has set its FY 2026 guidance at 2.090-2.240 EPS and its Q3 2026 guidance at 0.540-0.590 EPS. On average, equities research analysts predict that iRadimed Corporation will post 1.98 earnings per share for the current fiscal year.

iRadimed Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, August 28th. Shareholders of record on Friday, August 14th were issued a $0.20 dividend. The ex-dividend date of this dividend was Friday, August 14th. This represents a $0.80 annualized dividend and a yield of 0.9%. iRadimed's payout ratio is currently 44.69%.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on IRMD shares. Weiss Ratings lowered iRadimed from a "buy (b-)" rating to a "hold (c+)" rating in a report on Monday, August 3rd. Wall Street Zen downgraded iRadimed from a "buy" rating to a "hold" rating in a report on Saturday, August 8th. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat.com, iRadimed currently has an average rating of "Moderate Buy" and a consensus target price of $120.00.

iRadimed Profile

iRadimed Corporation designs, develops and manufactures medical device solutions for MRI environments. The company's core product line consists of MRI-compatible infusion systems engineered to deliver precise fluid management during magnetic resonance imaging procedures. These devices are crafted to minimize electrical noise and interference, ensuring both patient safety and image clarity in diagnostic and interventional settings.

In addition to infusion pumps, iRadimed offers a range of complementary accessories and monitoring solutions tailored to MRI suites.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.